{"id":"W2945661283","doi":"10.1200/jco.19.00315","title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":256,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Internal medicine; Dacarbazine; Adverse effect; Neutropenia; Clinical endpoint; Tolerability; Rash; Oncology; Surgery; Cancer; Chemotherapy; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001091047,0.0004570699,0.0007729653,0.0001426545,0.0001920388,0.0005908382,0.0003829669,0.0004857696,0.001130068],"category_scores_gemma":[0.0004635688,0.0001745462,0.0005258492,0.0001383191,0.0002512251,0.0002314842,0.0001856802,0.0008071689,0.0002272017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005978796,"about_ca_system_score_gemma":0.0006529783,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007477478,"about_ca_topic_score_gemma":0.00270131,"domain_scores_codex":[0.999827,0.00009246181,0.00000799212,0.00002299463,0.00002432377,0.00002527208],"domain_scores_gemma":[0.9996837,0.00005255533,0.00006602012,0.00002478632,0.00002512261,0.0001477949],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6183884,0.02266167,0.0555133,0.001882698,0.003121175,0.0005523812,0.0002507986,0.004679647,0.06827111,0.0006057025,0.01475039,0.2093227],"study_design_scores_gemma":[0.6216877,0.2420591,0.1084301,0.000144104,0.001632626,0.0007231651,0.00007334021,0.003893883,0.008003608,0.0003053277,0.01298797,0.0000592492],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929248,0.00368093,0.0002412274,0.0002079381,0.00006052609,0.0006886944,0.0008732101,0.0000516829,0.001270992],"genre_scores_gemma":[0.9933767,0.001553947,0.0006784127,0.0007761487,0.00011586,0.0006213614,0.001811182,0.00001118368,0.001055411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001130068,"threshold_uncertainty_score":0.005770087,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07774469496044747,"score_gpt":0.4610485409977395,"score_spread":0.383303846037292,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}